Posted by Michael Wonder on 20 Oct 2018
Highlights from CHMP 15-18 October 2018 meeting
19 October 2018 - The CHMP recommended six medicines for approval, three extensions of indications and elected its new vice-chair at its October 2018 meeting.
The CHMP recommended granting a marketing authorisation for Takhzyro (lanadelumab), the first monoclonal antibody therapy for the prevention of recurrent attacks of hereditary angioedema. This medicine was reviewed under EMA's accelerated assessment procedure, reserved for medicines of major public health interest.
